Trial Profile
Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2018.
- 08 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2018.
- 08 Oct 2017 Planned initiation date changed from 1 Jun 2016 to 1 Nov 2017.